Statins: Not just for cholesterol

Trends in Endocrinology and Metabolism

Volumn 11, Issue 7, 2000, Pages 255-256

  Toledano, James E ^a   Partridge, Nicola C ^b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CHOLESTEROL; COMPACTIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

BONE METABOLISM; CARDIOVASCULAR DISEASE; CHOLESTEROL METABOLISM; DRUG EFFECT; DRUG MECHANISM; HUMAN; MORBIDITY; MORTALITY; NONHUMAN; NORTHERN BLOTTING; NOTE; OSTEOCLAST; PRIORITY JOURNAL; STROKE;

NON-PROGRAMMATIC;

ANIMALS; ANTICHOLESTEREMIC AGENTS; BONE RESORPTION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OSTEOCLASTS;

EID: 0033845712     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(00)00295-2     Document Type: Note

References (7)

1. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: An overview of randomized trials
2. Stimulation of bone formation in vitro and in rodents by statins
3. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras
4. Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro
5. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates
6. Protein prenylation: Molecular mechanisms and functional consequences
7. Farnesyltransferase inhibitors: A new class of cancer chemotherapeutics